US · ETON · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Eton Pharmaceuticals, Inc. (ETON) intrinsic value and stock valuation
$60.85as of 2026-11-21 · Mkt cap 1.22B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Eton Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values ETON with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from ETON’s statements →
Eton Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Lexicon Pharmaceuticals, Inc. (LXRX) $1.53
- Omeros Corporation (OMER) $13.21
- Monopar Therapeutics Inc. (MNPR) $69.00
- Ocugen, Inc. (OCGN) $0.77
- Neumora Therapeutics, Inc. Common Stock (NMRA) $0.33
- Bicycle Therapeutics plc (BCYC) $2.90
- Fulcrum Therapeutics, Inc. (FULC) $3.69
- ADC Therapeutics S.A. (ADCT) $1.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80M | $39M | $31.6M | $21.3M | $21.8M |
| Operating income | $70K | -$-2.6M | -$-1.19M | -$-8.26M | -$-1.5M |
| Net income | -$-4.6M | -$-3.82M | -$-940K | -$-9.02M | -$-1.96M |
| EPSd | -$-170.94K | -$-147.55K | -$-36.65K | -$-358.65K | -$-77.75K |
| Operating cash flow | $10.5M | $970K | $6.82M | $4.82M | -$-4.72M |
| Capital expenditure | -$-330K | -$-30K | -$-780K | -$-2.79M | -$-3.26M |
| Free cash flow | $10.2M | $940K | $6.04M | $2.03M | -$-7.98M |
| Total assets | $92.1M | $76.1M | $31.7M | $25M | $27.5M |
| Total debt | $31M | $30M | $5.4M | $6.52M | $6.7M |
| Net debt | $5.08M | $15.1M | -$-15.99M | -$-9.78M | -$-7.71M |
| Total equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M |
| Cash and short-term investments | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $80M | $39M | $31.6M | $21.3M | $21.8M |
| Cost of revenue | $37.2M | $15.6M | $10.6M | $6.93M | $2.62M |
| Gross profit | $42.7M | $23.4M | $21.1M | $14.3M | $19.2M |
| Research and development expenses | $7.76M | $3.25M | $3.32M | $4M | $6.24M |
| Selling, general and administrative expenses | $35.8M | $22.8M | $18.9M | $18.6M | $14.5M |
| Other expenses | -$-920K | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $42.7M | $26M | $22.3M | $22.6M | $20.7M |
| Cost and expenses | $79.9M | $41.6M | $32.8M | $29.5M | $23.3M |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $4.78M | $2M | $1.06M | $950K | $1.04M |
| Depreciation and amortization | $4.04M | $1.15M | $900K | $1.77M | $460K |
| Ebitda | $4.27M | -$-660K | $210K | -$-7.25M | -$-1.49M |
| Operating income | $70K | -$-2.6M | -$-1.19M | -$-8.26M | -$-1.5M |
| Total other income/expenses, net | -$-4.63M | -$-1.21M | $500K | -$-760K | -$-460K |
| Income before tax | -$-4.56M | -$-3.81M | -$-690K | -$-9.02M | -$-1.96M |
| Income tax expense | $40K | $10K | $250K | $0.00 | $0.00 |
| Net income | -$-4.6M | -$-3.82M | -$-940K | -$-9.02M | -$-1.96M |
| Weighted average shares outstanding | $26.9M | $25.9M | $25.6M | $25.2M | $25.2M |
| Weighted average diluted shares outstanding | $26.9M | $25.9M | $25.7M | $25.2M | $25.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M |
| Net receivables | $11.8M | $5.36M | $3.41M | $1.85M | $5.47M |
| Inventory | $15.4M | $15.2M | $910K | $560K | $550K |
| Total current assets | $60.6M | $41M | $26.8M | $20M | $23.6M |
| Property, plant and equipment, net | $640K | $210K | $150K | $260K | $220K |
| Goodwill and intangible assets | $30.9M | $34.9M | $4.74M | $4.75M | $3.62M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $31.5M | $35.1M | $4.9M | $5.03M | $3.86M |
| Total assets | $92.1M | $76.1M | $31.7M | $25M | $27.5M |
| Accounts payable | $11M | $4.17M | $1.85M | $1.77M | $1.77M |
| Short-term debt | $8.79M | $80K | $5.38M | $1.03M | $1.42M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $38.5M | $20M | $16.2M | $6.46M | $4.56M |
| Long-term debt | $22.2M | $29.9M | $20K | $5.49M | $5.28M |
| Deferred revenue, non-current | $1.76M | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $27.5M | $31.8M | $20K | $5.49M | $5.28M |
| Capital lease obligations | $460K | $110K | $20K | $110K | $10K |
| Total liabilities | $66M | $51.7M | $16.3M | $12M | $9.84M |
| Common stock | $30K | $30K | $30K | $30K | $30K |
| Retained earnings | -$-112.49M | -$-107.89M | -$-104.07M | -$-103.13M | -$-94.11M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $26.2M | $24.4M | $15.5M | $13.1M | $17.6M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $31M | $30M | $5.4M | $6.52M | $6.7M |
| Net debt | $5.08M | $15.1M | -$-15.99M | -$-9.78M | -$-7.71M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-4.6M | -$-3.82M | -$-940K | -$-9.02M | -$-1.96M |
| Depreciation and amortization | $4.04M | $1.15M | $900K | $1.77M | $460K |
| Stock-based compensation | $5.51M | $3.17M | $3.14M | $4.22M | $3.38M |
| Change in working capital | -$-860K | -$-700K | $3.53M | $7.66M | -$-6.21M |
| Accounts receivable | -$-6.4M | -$-3.12M | -$-1.56M | $3.62M | -$-5.42M |
| Inventory | -$-5.88M | -$-1.31M | -$-350K | -$-10K | $690K |
| Accounts payable | $6.81M | $2.32M | $50K | -$-10K | -$-570K |
| Net cash provided by operating activities | $10.5M | $970K | $6.82M | $4.82M | -$-4.72M |
| Investments in property, plant and equipment | -$-330K | -$-30K | -$-780K | -$-40K | -$-3.26M |
| Acquisitions, net | $0.00 | -$-30M | $0.00 | $0.00 | $700K |
| Net cash used for investing activities | -$-330K | -$-40.01M | -$-780K | -$-2.79M | -$-2.56M |
| Common stock issued | $600K | $8.19M | $0.00 | $0.00 | $540K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $810K | $32.6M | -$-960K | -$-130K | $390K |
| Net change in cash | $11M | -$-6.45M | $5.08M | $1.9M | -$-6.89M |
| Cash at end of period | $25.9M | $14.9M | $21.4M | $16.3M | $14.4M |
| Operating cash flow | $10.5M | $970K | $6.82M | $4.82M | -$-4.72M |
| Capital expenditure | -$-330K | -$-30K | -$-780K | -$-2.79M | -$-3.26M |
| Free cash flow | $10.2M | $940K | $6.04M | $2.03M | -$-7.98M |
Line items
Line items
Line items
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
- CEO
- Sean E. Brynjelsen
- Employees
- 44
- Beta
- 0.86
Explore
Frequently asked questions
What is the intrinsic value of Eton Pharmaceuticals, Inc. (ETON)?
Eton Pharmaceuticals, Inc. (ETON) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ETON undervalued?
ETON trades at a price of $60.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.